File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Factor VIII Von Willebrand factor antigen levels correlaie with symptom severity in patients with Raynaud's phenomenon

TitleFactor VIII Von Willebrand factor antigen levels correlaie with symptom severity in patients with Raynaud's phenomenon
Authors
Issue Date1991
PublisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
Citation
British Journal Of Rheumatology, 1991, v. 30 n. 6, p. 433-436 How to Cite?
AbstractWe have previously documented raised levels of factor VIII von Willebrand factor antigen (FVIII vWF Ag), an endothelial product, in patients with vascular diseases and suggested that levels of this relate to disease activity. No one has yet investigated patients with Raynaud's phenomenon (RP) alone to see if the severity of vasospastic attacks relates to FVIII vWF Ag. We studied 22 patients with RP. None of these patients fulfilled diagnostic criteria for a connective tissue disease but all had severe symptoms which warranted referral to hospital. We measured the FVIII vWF Ag and the procoagulant factor VIII (FVIlI:c) levels in these patients. FVIII:c is not an endothelial product and is released by different mechanisms, thus It forms an active control to FVIII vWF Ag. FVIII vWF Ag measurements were carried out using the Laurell method and FVIII: c was assessed using the technique described by Nilsson. Patients were asked to complete diaries over a 2-week winter period. The frequency and duration of all Raynaud's attacks were recorded. There were significant positive correlations between FVIII vWF Ag and the total number and duration of RP attacks over the 2-week period (P < 0.005, r = 0.67 and P < 0.05, r = 0.40, respectively; Spearman's rank correlation). No correlation was found between levels of FVIII:c and the same clinical parameters. It has been suggested that patients with clinical evidence of vascular damage have elevated plasma levels of FVIII vWF Ag. Our present study has demonstrated correlations between FVIII vWF Ag levels and the clinical severity of vasospasm in patients with RP. Whether severe blood vessel spasm causes an increase in FVIII vWF Ag release or patients with blood vessel damage have more severe attacks of RP is not yet clear; however, FVIII vWF Ag levels may serve as a marker of disease activity in these patients.
Persistent Identifierhttp://hdl.handle.net/10722/161915
ISSN
2000 Impact Factor: 3.949
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, CSen_US
dc.contributor.authorMclaren, Men_US
dc.contributor.authorBelch, JJFen_US
dc.date.accessioned2012-09-05T05:16:00Z-
dc.date.available2012-09-05T05:16:00Z-
dc.date.issued1991en_US
dc.identifier.citationBritish Journal Of Rheumatology, 1991, v. 30 n. 6, p. 433-436en_US
dc.identifier.issn0263-7103en_US
dc.identifier.urihttp://hdl.handle.net/10722/161915-
dc.description.abstractWe have previously documented raised levels of factor VIII von Willebrand factor antigen (FVIII vWF Ag), an endothelial product, in patients with vascular diseases and suggested that levels of this relate to disease activity. No one has yet investigated patients with Raynaud's phenomenon (RP) alone to see if the severity of vasospastic attacks relates to FVIII vWF Ag. We studied 22 patients with RP. None of these patients fulfilled diagnostic criteria for a connective tissue disease but all had severe symptoms which warranted referral to hospital. We measured the FVIII vWF Ag and the procoagulant factor VIII (FVIlI:c) levels in these patients. FVIII:c is not an endothelial product and is released by different mechanisms, thus It forms an active control to FVIII vWF Ag. FVIII vWF Ag measurements were carried out using the Laurell method and FVIII: c was assessed using the technique described by Nilsson. Patients were asked to complete diaries over a 2-week winter period. The frequency and duration of all Raynaud's attacks were recorded. There were significant positive correlations between FVIII vWF Ag and the total number and duration of RP attacks over the 2-week period (P < 0.005, r = 0.67 and P < 0.05, r = 0.40, respectively; Spearman's rank correlation). No correlation was found between levels of FVIII:c and the same clinical parameters. It has been suggested that patients with clinical evidence of vascular damage have elevated plasma levels of FVIII vWF Ag. Our present study has demonstrated correlations between FVIII vWF Ag levels and the clinical severity of vasospasm in patients with RP. Whether severe blood vessel spasm causes an increase in FVIII vWF Ag release or patients with blood vessel damage have more severe attacks of RP is not yet clear; however, FVIII vWF Ag levels may serve as a marker of disease activity in these patients.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/en_US
dc.relation.ispartofBritish Journal of Rheumatologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshBiological Markers - Blooden_US
dc.subject.meshFactor Viii - Metabolismen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRaynaud Disease - Blood - Immunologyen_US
dc.subject.meshSmoking - Blooden_US
dc.subject.meshVon Willebrand Factor - Metabolismen_US
dc.titleFactor VIII Von Willebrand factor antigen levels correlaie with symptom severity in patients with Raynaud's phenomenonen_US
dc.typeArticleen_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1747698-
dc.identifier.scopuseid_2-s2.0-0026409851en_US
dc.identifier.volume30en_US
dc.identifier.issue6en_US
dc.identifier.spage433en_US
dc.identifier.epage436en_US
dc.identifier.isiWOS:A1991GU03300010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US
dc.identifier.scopusauthoridMcLaren, M=7005471705en_US
dc.identifier.scopusauthoridBelch, JJF=7101752870en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats